2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12D.04 Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

P3.12D.04 Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

Back to course

Pdf Summary

The Phase 2 COCOON study is an ongoing, open-label, randomized clinical trial aimed at evaluating the impact of enhanced versus standard dermatologic management in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) possessing EGFR mutations. These patients receive first-line treatment with amivantamab and lazertinib. Amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a third-generation EGFR-TKI, have shown significant improvement in progression-free survival in previous studies. The study is notable for its focus on dermatological adverse events (DAEs), such as rash and skin irritation, associated with EGFR-targeted therapies, which can negatively affect patients’ quality of life and treatment adherence.<br /><br />COCOON explores whether proactive, enhanced skincare measures can reduce the occurrence of these dermatologic side effects. Participants are divided into two groups: one receiving standard dermatologic management and the other receiving an enhanced regimen that includes prophylactic antibiotics, skin moisturization, and paronychia prevention strategies.<br /><br />Patient eligibility includes those with treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC, and participants are stratified by race and age. The primary aim is to assess the incidence of grade 2 dermatologic adverse events during the initial 12 weeks of treatment.<br /><br />The study intends to enroll 180 patients across 78 sites in the US, EU, Asia-Pacific, and Latin America. Its secondary objectives include evaluating dermatologic toxicity and the impact of enhanced management on quality of life and treatment compliance. The trial is currently recruiting participants. The study is funded by Janssen Research & Development, LLC, and results are anticipated to provide insights into optimizing dermatologic care in NSCLC treatments.

Asset Subtitle

Byoung Chul Cho

Meta Tag

Speaker Byoung Chul Cho

Topic Metastatic NSCLC – Targeted Therapy

Keywords

COCOON study

NSCLC

EGFR mutations

amivantamab

lazertinib

dermatologic adverse events

enhanced skincare

clinical trial

progression-free survival

Janssen Research